Skip to search formSkip to main contentSkip to account menu
You are currently offline. Some features of the site may not work correctly.

CDX-110

Known as: CDX 110, CDX110 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Summary Background Rindopepimut (also known as CDX-110), a vaccine targeting the EGFR deletion mutation EGFRvIII, consists of an… 
Highly Cited
2015
Highly Cited
2015
BACKGROUND The epidermal growth factor receptor variant III deletion mutation, EGFRvIII, is expressed in ∼30% of primary… 
Highly Cited
2015
Highly Cited
2015
2009 Background: EGFRvIII, a constitutively active EGFR deletion driver mutation, is associated with poor long-term survival in… 
Review
2015
Review
2015
BACKGROUND: EGFRvIII, a constitutively active EGFR deletion driver mutation, is associated with poor long-term survival in… 
2015
2015
G lioblastoma multiforme (GBM) is the most common primary brain tumor in adults. Standard therapy, including maximal surgical… 
2014
2014
BACKGROUND: EGFRvIII, a constitutively active tumorigenic EGFR deletion mutation, is linked to poor long-term survival. The… 
2010
2010
2014 Background: EGFRvIII is a constitutively activated mutation of EGFR, not expressed in normal tissues but expressed in GBM… 
Review
2009
Review
2009
Conventional therapies for glioblastoma multiforme (GBM) fail to target tumor cells exclusively, resulting in non-specific… 
2009
2009
2021 Background: Unlike conventional therapies for GBM, immunologic targeting of tumor-specific gene mutations allows precise… 
2008
2008
2011 Background: Conventional therapies for GBM fail to target tumor cells exclusively. Immunologic targeting of tumor- specific…